NA
RMD icon

Navellier & Associates’s ResMed RMD Stock Holding History

Navellier & Associates’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,438
Closed -$3.92M – 314
2020
Q4 		$3.92M Buy
18,438
+2,070
+13% +$413K 0.71% 51
2020
Q3 		$2.81M Sell
16,368
-4,641
-22% -$857K 0.61% 55
2020
Q2 		$4.03M Buy
21,009
+681
+3% +$111K 0.96% 29
2020
Q1 		$2.99M Buy
+20,328
New +$3.24M 0.7% 37
2016
Q1 		– Sell
-3,800
Closed -$204K – 286
2015
Q4 		$204K Buy
+3,800
New +$214K 0.02% 207
2014
Q1 		– Sell
-4,331
Closed -$203K – 344
2013
Q4 		$203K Sell
4,331
-790,108
-99% -$40M 0.01% 301
2013
Q3 		$42M Sell
794,439
-6,933
-0.9% -$336K 1.24% 44
2013
Q2 		$36.2M Buy
+801,372
New +$38M 1.72% 31

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Navellier & Associates's RMD Position: Q1 2021 in Review

Navellier & Associates sold out of ResMed (RMD) in Q1 2021, closing a stake of 18,438 shares — an estimated $3.92M sold.

Navellier & Associates first reported a position in RMD in Q2 2013 and held it in 8 quarters. The position peaked at $42M in Q3 2013. 662 funds tracked by Wall St. Rank hold RMD as of Q1 2021.

  • Navellier & Associates reported no remaining ResMed position as of Q1 2021 after selling out during the quarter.
  • Navellier & Associates sold 18,438 ResMed shares in Q1 2021, an estimated $3.92M.
  • Navellier & Associates first reported a position in ResMed in Q2 2013 and held it in 8 quarters.
  • Navellier & Associates's ResMed position peaked at $42M in Q3 2013.
  • 662 funds tracked by Wall St. Rank held ResMed as of Q1 2021.

Based on Navellier & Associates's 13F filing for Q1 2021, filed 12 May 2021.